Literature DB >> 11316178

Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function.

A M Madrid1, C Hurtado, M Venegas, F Cumsille, C Defilippi.   

Abstract

OBJECTIVES: Altered small-bowel motility, lengthening of the orocecal transit time, and small-intestinal bacterial overgrowth have been described in patients with liver cirrhosis. These changes might be related to the progressive course and poor prognosis of the disease. We investigated the effect of a long-term treatment with cisapride and an antibiotic regimen on small-intestinal motor activity, orocecal transit time, bacterial overgrowth, and some parameters of liver function.
METHODS: Thirty-four patients with liver cirrhosis of different etiology entered in the study. They were randomly allocated to receive cisapride (12), an alternating regimen of norfloxacin and neomycin (12), or placebo (10) during a period of 6 months. At entry and at 3 and 6 months, a stationary small-intestinal manometry was performed, and orocecal transit time and small-intestinal bacterial overgrowth were also investigated using the H2 breath test. Liver function was estimated with clinical and laboratory measurements (Child-Pugh score).
RESULTS: After 6 months, both cisapride and antibiotics significantly improved fasting cyclic activity, reduced the duration of orocecal transit time, and decreased small-intestinal bacterial overgrowth. Cisapride administration was followed also by an increase in the amplitude of contractions. No statistically significant variations in these parameters were observed with placebo. An improvement of liver function was observed at 3 and 6 months with both cisapride and antibiotics.
CONCLUSIONS: Long-term treatment with cisapride or antibiotics reversed altered small-intestinal motility and bacterial overgrowth in patients with liver cirrhosis. These findings suggest a possible role for prokinetics and antibiotics as a modality of treatment in selected cases of decompensated cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11316178     DOI: 10.1111/j.1572-0241.2001.03636.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  50 in total

1.  Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment.

Authors:  Virmeet V. Singh; Phillip P. Toskes
Journal:  Curr Treat Options Gastroenterol       Date:  2004-02

2.  Small intestinal clustered contractions and bacterial overgrowth: a frequent finding in obese patients.

Authors:  Ana María Madrid; Jaime Poniachik; Rodrigo Quera; Carlos Defilippi
Journal:  Dig Dis Sci       Date:  2010-05-01       Impact factor: 3.199

Review 3.  Alcoholic liver disease: the gut microbiome and liver cross talk.

Authors:  Phillipp Hartmann; Caroline T Seebauer; Bernd Schnabl
Journal:  Alcohol Clin Exp Res       Date:  2015-05       Impact factor: 3.455

Review 4.  Infection, coagulation, and variceal bleeding in cirrhosis.

Authors:  U Thalheimer; C K Triantos; D N Samonakis; D Patch; A K Burroughs
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 5.  Gut flora and bacterial translocation in chronic liver disease.

Authors:  John Almeida; Sumedha Galhenage; Jennifer Yu; Jelica Kurtovic; Stephen M Riordan
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

Review 6.  A systematic review of diagnostic tests for small intestinal bacterial overgrowth.

Authors:  Reza Khoshini; Sun-Chuan Dai; Sheila Lezcano; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

7.  The role of the gut microbiota in nonalcoholic fatty liver disease.

Authors:  Ahmed Abu-Shanab; Eamonn M M Quigley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

Review 8.  Microbiota-based treatments in alcoholic liver disease.

Authors:  Hotaik Sung; Seung Woo Kim; Meegun Hong; Ki Tae Suk
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

9.  Targeting the gut barrier for the treatment of alcoholic liver disease.

Authors:  Zhanxiang Zhou; Wei Zhong
Journal:  Liver Res       Date:  2017-12

10.  Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis.

Authors:  Roman Maslennikov; Chavdar Pavlov; Vladimir Ivashkin
Journal:  Hepatol Int       Date:  2018-10-04       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.